{{proofreader needed}}
{{medical}}

{{NoteTA
|G1=IT
|1=zh-cn:通过;zh-tw:透過;
|2=zh-cn:从而;zh-tw:進而;
}}

[[File:RNA_vaccine_illustration_(zh).jpg|thumb]]
'''mRNA疫苗'''是一种利用[[信使RNA|信使RNA]]（mRNA）的分子副本来产生[[免疫反应|免疫反应]]的[[疫苗|疫苗]]。<ref name="#1">{{Cite journal|title=Non-viral COVID-19 vaccine delivery systems|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744276/|last=Park|first=Kyung Soo|last2=Sun|first2=Xiaoqi|date=2021-2|journal=Advanced Drug Delivery Reviews|doi=10.1016/j.addr.2020.12.008|volume=169|pages=137–151|issn=0169-409X|pmc=7744276|pmid=33340620|last3=Aikins|first3=Marisa E.|last4=Moon|first4=James J.|access-date=2021-11-10|archive-date=2022-03-25|archive-url=https://web.archive.org/web/20220325164759/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744276/}}</ref>此类疫苗将编码抗原的mRNA分子送入免疫细胞，免疫细胞使用设计好的mRNA作为模板来构建通常由病原体（如病毒）或癌细胞产生的外来蛋白质。这些蛋白质分子刺激适应性免疫反应，教导身体识别并摧毁相应的病原体或癌细胞。<ref name="#1"/> mRNA是由封装在[[脂质纳米颗粒|脂质纳米颗粒]]中的RNA共同组成，保护RNA链并帮助其吸收进入细胞。<ref>{{Cite journal|title=Three decades of messenger RNA vaccine development|url=http://hdl.handle.net/1854/LU-8628303|last=Verbeke|first=Rein|last2=Lentacker|first2=Ine|date=2019|journal=NANO TODAY|doi=10.1016/j.nantod.2019.100766|volume=28|issn=1748-0132|last3=De Smedt|first3=Stefaan|last4=Dewitte|first4=Heleen}}</ref><ref>{{Cite journal|title=Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6453548/|last=Kowalski|first=Piotr S.|last2=Rudra|first2=Arnab|date=2019-04-10|journal=Molecular Therapy|issue=4|doi=10.1016/j.ymthe.2019.02.012|volume=27|pages=710–728|issn=1525-0016|pmc=6453548|pmid=30846391|last3=Miao|first3=Lei|last4=Anderson|first4=Daniel G.|access-date=2021-11-10|archive-date=2022-02-20|archive-url=https://web.archive.org/web/20220220204036/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6453548/}}</ref>

反应原性（即疫苗产生不良反应的倾向）与传统的非RNA疫苗相似。<ref name="#2">{{Cite journal|title=mRNA vaccines — a new era in vaccinology|url=https://www.nature.com/articles/nrd.2017.243|last=Pardi|first=Norbert|last2=Hogan|first2=Michael J.|date=2018-04|journal=Nature Reviews Drug Discovery|issue=4|doi=10.1038/nrd.2017.243|volume=17|pages=261–279|language=en|issn=1474-1784|last3=Porter|first3=Frederick W.|last4=Weissman|first4=Drew|access-date=2021-11-10|archive-date=2022-01-24|archive-url=https://web.archive.org/web/20220124192524/https://www.nature.com/articles/nrd.2017.243}}</ref> 容易产生自身免疫反应的人可能会对信使RNA疫苗产生不良反应。<ref name="#2"/>与传统疫苗相比，mRNA疫苗的优点是易于设计、生产速度快、成本低、能诱导细胞免疫和体液免疫，并且不与基因组DNA相互作用。 <ref name="#3">{{Cite web|title=RNA vaccines: an introduction|url=https://www.phgfoundation.org/briefing/rna-vaccines|access-date=2021-11-10|work=PHG Foundation|language=en|archive-date=2020-08-24|archive-url=https://web.archive.org/web/20200824194130/https://www.phgfoundation.org/briefing/rna-vaccines}}</ref> 虽然一些信使RNA疫苗，如[[輝瑞|輝瑞]]生物技术公司的[[2019冠状病毒病疫苗|COVID-19疫苗]]，有在分发前需要超低温储存的缺点，<ref name="#1"/> 但其他mRNA疫苗，如[[莫德納|莫德納]]、CureVac和Walvax COVID-19疫苗，没有这种要求。<ref>{{Cite news|title=Mexico to start late-stage clinical trial for China's mRNA COVID-19 vaccine|url=https://www.reuters.com/business/healthcare-pharmaceuticals/mexico-start-phase-iii-clinical-trials-chinas-walvax-covid-vaccine-2021-05-11/|newspaper=Reuters|date=2021-05-11|accessdate=2021-11-10|language=en|last=Reuters|archive-date=2021-08-23|archive-url=https://web.archive.org/web/20210823100114/https://www.reuters.com/business/healthcare-pharmaceuticals/mexico-start-phase-iii-clinical-trials-chinas-walvax-covid-vaccine-2021-05-11/}}</ref><ref>{{Cite journal|title=Addressing the Cold Reality of mRNA Vaccine Stability|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834447/|last=Crommelin|first=Daan J.A.|last2=Anchordoquy|first2=Thomas J.|date=2021-3|journal=Journal of Pharmaceutical Sciences|issue=3|doi=10.1016/j.xphs.2020.12.006|volume=110|pages=997–1001|issn=0022-3549|pmc=7834447|pmid=33321139|last3=Volkin|first3=David B.|last4=Jiskoot|first4=Wim|last5=Mastrobattista|first5=Enrico|access-date=2021-11-10|archive-date=2022-01-30|archive-url=https://web.archive.org/web/20220130153422/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834447/}}</ref>

在RNA疗法中，信使RNA疫苗作为COVID-19疫苗引起了相当大的兴趣。<ref name="#1"/> 2020年12月，辉瑞生物技术公司和莫德納公司的基于mRNA的COVID-19疫苗获得批准。12月2日，英国药品和保健品管理局（MHRA）成为第一个批准mRNA疫苗的药品监管机构，授权辉瑞生物技术公司的疫苗使用。<ref name="#4">{{Cite web|title=UK authorises Pfizer/BioNTech COVID-19 vaccine|url=https://www.gov.uk/government/news/uk-authorises-pfizer-biontech-covid-19-vaccine|access-date=2021-11-10|work=GOV.UK|language=en|archive-date=2020-12-02|archive-url=https://web.archive.org/web/20201202070233/https://www.gov.uk/government/news/uk-authorises-pfizer-biontech-covid-19-vaccine}}</ref><ref name="#5">{{Cite web|title=UK approves Pfizer/BioNTech Covid vaccine for rollout next week|url=http://www.theguardian.com/society/2020/dec/02/pfizer-biontech-covid-vaccine-wins-licence-for-use-in-the-uk|access-date=2021-11-10|date=2020-12-02|work=the Guardian|language=en|archive-date=2021-05-16|archive-url=https://web.archive.org/web/20210516003436/https://www.theguardian.com/society/2020/dec/02/pfizer-biontech-covid-vaccine-wins-licence-for-use-in-the-uk}}</ref><ref>{{Cite web|title=Conditions of Authorisation for COVID-19 Vaccine Pfizer/BioNTech (Regulation 174)|url=https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19/conditions-of-authorisation-for-pfizerbiontech-covid-19-vaccine|access-date=2021-11-10|work=GOV.UK|language=en|archive-date=2021-02-26|archive-url=https://web.archive.org/web/20210226081445/https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19/conditions-of-authorisation-for-pfizerbiontech-covid-19-vaccine}}</ref> 12月11日，美国食品和药物管理局（[[美国食品药品监督管理局|FDA]]）为[[輝瑞|輝瑞]]生物技术公司的疫苗颁发了紧急使用授权<ref>{{Cite web|title=FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine|url=https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19|access-date=2021-11-10|date=2020-12-14|last=Commissioner|first=Office of the|work=FDA|language=en|archive-date=2021-03-18|archive-url=https://web.archive.org/web/20210318070621/https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19}}</ref><ref>{{Cite journal|title=The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine — United States, December 2020|author=Sara E. Oliver|url=https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6950e2-H.pdf|journal=Morbidity and Mortality Weekly Report 1922 MMWR / December 18, 2020 / Vol. 69 / No. 50US Department of Health and Human Services/Centers for Disease Control and Prevention The Advisory Committee on Immunization Practices’ Interim Recommendation  for Use of Pfizer-BioNTech COVID-19 Vaccine — United States, December 2020|access-date=2021-11-10|archive-date=2020-12-19|archive-url=https://web.archive.org/web/20201219193006/https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6950e2-H.pdf}}</ref>，一周后同样批准了[[莫德纳|莫德纳]]的疫苗。<ref>{{Cite journal|title=The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020|author=Sara E|url=https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm695152e1-H.pdf|journal=The Advisory Committee on Immunization Practices’ Interim Recommendation  for Use of Moderna COVID-19 Vaccine — United States, December 2020|access-date=2021-11-10|archive-date=2021-02-09|archive-url=https://web.archive.org/web/20210209193446/https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm695152e1-H.pdf}}</ref><ref>{{Cite web|title=FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine|url=https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid|access-date=2021-11-10|date=2020-12-21|last=Commissioner|first=Office of the|work=FDA|language=en|archive-date=2021-03-17|archive-url=https://web.archive.org/web/20210317151347/https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid}}</ref>

==历史==
=== 早期研究 ===
1989年发表了第一篇成功将脂质体纳米颗粒中的mRNA转染到细胞中的文章。<ref name="#6">{{Cite journal|title=mRNA Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7554980/|last=Xu|first=Shuqin|last2=Yang|first2=Kunpeng|date=2020-09-09|journal=International Journal of Molecular Sciences|issue=18|doi=10.3390/ijms21186582|volume=21|pages=6582|issn=1422-0067|pmc=7554980|pmid=32916818|last3=Li|first3=Rose|last4=Zhang|first4=Lu|access-date=2021-11-10|archive-date=2021-01-09|archive-url=https://web.archive.org/web/20210109215715/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7554980/}}</ref><ref>{{Cite journal|title=Cationic liposome-mediated RNA transfection.|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC297778/|last=Malone|first=R W|last2=Felgner|first2=P L|date=1989-08|journal=Proceedings of the National Academy of Sciences of the United States of America|issue=16|volume=86|pages=6077–6081|issn=0027-8424|pmid=2762315|last3=Verma|first3=I M|access-date=2021-11-10|archive-date=2022-04-07|archive-url=https://web.archive.org/web/20220407001950/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC297778/}}</ref>一年后，无保护的mRNA被注射到[[實驗小鼠|實驗小鼠]]的肌肉中。<ref>{{Cite journal|title=Direct Gene Transfer into Mouse Muscle in Vivo|url=https://www.science.org/doi/10.1126/science.1690918|last=Wolff|first=Jon A.|last2=Malone|first2=Robert W.|date=1990-03-23|journal=Science|issue=4949|doi=10.1126/science.1690918|volume=247|pages=1465–1468|last3=Williams|first3=Phillip|last4=Chong|first4=Wang|last5=Acsadi|first5=Gyula|last6=Jani|first6=Agnes|last7=Felgner|first7=Philip L.|access-date=2021-11-10|archive-date=2022-04-18|archive-url=https://web.archive.org/web/20220418052247/https://www.science.org/doi/10.1126/science.1690918}}</ref> 这些研究首次证明体外转录的mRNA能够传递[[遗传信息|遗传信息]]，在活细胞组织中产生蛋白质并导致信使RNA疫苗的概念提出。<ref name="#6"/>

1993年，脂质体包裹的mRNA被证明可以刺激小鼠的[[T细胞|T细胞]]。<ref name="#6"/><ref>{{Cite journal|title=Messenger RNA-based vaccines|url=https://doi.org/10.1517/14712598.4.8.1285|last=Pascolo|first=Steve|date=2004-08-01|journal=Expert Opinion on Biological Therapy|issue=8|doi=10.1517/14712598.4.8.1285|volume=4|pages=1285–1294|issn=1471-2598|pmid=15268662}}</ref> 次年，通过包括病毒抗原和複製酶编码基因，开发了自我複製的mRNA。<ref>{{Cite journal|title=Self-replicating Semliki Forest virus RNA as recombinant vaccine|url=https://pubmed.ncbi.nlm.nih.gov/7879415/|last=Zhou|first=X.|last2=Berglund|first2=P.|date=1994-12|journal=Vaccine|issue=16|doi=10.1016/0264-410x(94)90074-4|volume=12|pages=1510–1514|issn=0264-410X|pmid=7879415|last3=Rhodes|first3=G.|last4=Parker|first4=S. E.|last5=Jondal|first5=M.|last6=Liljeström|first6=P.|access-date=2021-11-10|archive-date=2021-11-10|archive-url=https://web.archive.org/web/20211110141738/https://pubmed.ncbi.nlm.nih.gov/7879415/}}</ref> 这种方法在小鼠身上引起了针对病毒病原体的体液和细胞免疫反应。第二年，编码肿瘤抗原的mRNA被证明在小鼠身上引起了针对癌细胞的类似免疫反应。<ref>{{Cite journal|title=A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991152/|last=Kallen|first=Karl-Josef|last2=Theß|first2=Andreas|date=2014-1|journal=Therapeutic Advances in Vaccines|issue=1|doi=10.1177/2051013613508729|volume=2|pages=10–31|issn=2051-0136|pmc=3991152|pmid=24757523|access-date=2021-11-10|archive-date=2021-12-01|archive-url=https://web.archive.org/web/20211201151339/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991152/}}</ref>

=== 发展 ===
2001年，第一个使用转染了编码肿瘤抗原的mRNA的体外[[树突状细胞|树突状细胞]]的人体临床试验（治疗性癌症mRNA疫苗）开展。<ref>{{Cite journal|title=Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors|url=https://www.jci.org/articles/view/14364|last=Heiser|first=Axel|last2=Coleman|first2=Doris|date=2002-02-01|journal=The Journal of Clinical Investigation|issue=3|doi=10.1172/JCI14364|volume=109|pages=409–417|language=en|issn=0021-9738|pmid=11828001|last3=Dannull|first3=Jens|last4=Yancey|first4=Donna|last5=Maurice|first5=Margaret A.|last6=Lallas|first6=Costas D.|last7=Dahm|first7=Philipp|last8=Niedzwiecki|first8=Donna|last9=Gilboa|first9=Eli|access-date=2021-11-10|archive-date=2021-10-14|archive-url=https://web.archive.org/web/20211014021402/https://www.jci.org/articles/view/14364}}</ref>四年后，报道了成功使用改性核苷作为在细胞内运输mRNA而不引起身体防御系统的方法。<ref>{{Cite journal|title=Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA|url=https://www.cell.com/immunity/abstract/S1074-7613(05)00211-6|last=Karikó|first=Katalin|last2=Buckstein|first2=Michael|date=2005-08-01|journal=Immunity|issue=2|doi=10.1016/j.immuni.2005.06.008|volume=23|pages=165–175|language=en|issn=1074-7613|pmid=16111635|last3=Ni|first3=Houping|last4=Weissman|first4=Drew}}</ref> 2008年报道了直接注射到体内对抗癌细胞的mRNA疫苗的临床试验结果。<ref name="#7">{{Cite journal|title=An Update on Self-Amplifying mRNA Vaccine Development|url=https://www.mdpi.com/2076-393X/9/2/97|last=Blakney|first=Anna K.|last2=Ip|first2=Shell|date=2021-02|journal=Vaccines|issue=2|doi=10.3390/vaccines9020097|volume=9|pages=97|language=en|last3=Geall|first3=Andrew J.|access-date=2021-11-10|archive-date=2021-10-06|archive-url=https://web.archive.org/web/20211006101306/https://www.mdpi.com/2076-393X/9/2/97}}</ref>

2008年成立了[[BioNTech|BioNTech]]公司，2010年成立了[[莫德納|莫德納]]公司，以开发mRNA生物技术。<ref>{{Cite web|title=The story of mRNA: From a loose idea to a tool that may help curb Covid|url=https://www.statnews.com/2020/11/10/the-story-of-mrna-how-a-once-dismissed-idea-became-a-leading-technology-in-the-covid-vaccine-race/|access-date=2021-11-10|date=2020-11-10|work=STAT|language=en-US|archive-date=2021-04-15|archive-url=https://web.archive.org/web/20210415010956/https://www.statnews.com/2020/11/10/the-story-of-mrna-how-a-once-dismissed-idea-became-a-leading-technology-in-the-covid-vaccine-race/}}</ref> 美国研究机构DARPA在此时启动了生物技术研究计划ADEPT，为美国军队开发新兴技术。<ref>{{Cite web|title=DARPA’s gambles might have created the best hopes for stopping COVID-19|url=https://www.biocentury.com/article/304691/darpa-s-gambles-might-have-created-the-best-hopes-for-stopping-covid-19|access-date=2021-11-10|last=Usdin|first=Steve|work=BioCentury|archive-date=2021-06-18|archive-url=https://web.archive.org/web/20210618100615/https://www.biocentury.com/article/304691/darpa-s-gambles-might-have-created-the-best-hopes-for-stopping-covid-19}}</ref>该机构认识到核酸技术在防御大流行病方面的潜力，并开始在该领域进行投资。

DARPA的拨款被视为一张信任票，鼓励了其他政府机构和私人投资者投资mRNA技术。<ref>{{Cite web|title=DARPA Awards Moderna Therapeutics A Grant For Up To $25 Million To Develop Messenger RNA Therapeutics™|url=https://www.prnewswire.com/news-releases/darpa-awards-moderna-therapeutics-a-grant-for-up-to-25-million-to-develop-messenger-rna-therapeutics-226115821.html|access-date=2021-11-10|last=Therapeutics|first=Moderna|work=www.prnewswire.com|language=en|archive-date=2021-09-04|archive-url=https://web.archive.org/web/20210904070546/https://www.prnewswire.com/news-releases/darpa-awards-moderna-therapeutics-a-grant-for-up-to-25-million-to-develop-messenger-rna-therapeutics-226115821.html}}</ref>

2013年开始了第一个使用mRNA疫苗对付传染病原体（狂犬病）的人体临床试验。<ref>{{Cite journal|title=The tangled history of mRNA vaccines|url=https://www.nature.com/articles/d41586-021-02483-w|last=Dolgin|first=Elie|date=2021-09-14|journal=Nature|issue=7876|doi=10.1038/d41586-021-02483-w|volume=597|pages=318–324|language=en|access-date=2021-11-10|archive-date=2021-12-27|archive-url=https://web.archive.org/web/20211227081912/https://www.nature.com/articles/d41586-021-02483-w}}</ref> 在接下来的几年里，开始了针对其他病毒的mRNA疫苗的临床试验。已经研究了用于人体的mRNA疫苗，如[[流感|流感]]、[[寨卡病毒|寨卡病毒]]、巨细胞病毒和[[基孔肯雅熱|基孔肯雅病毒]]等传染病。<ref>{{Cite journal|title=Lipid nanoparticles for mRNA delivery|url=https://www.nature.com/articles/s41578-021-00358-0|last=Hou|first=Xucheng|last2=Zaks|first2=Tal|date=2021-08-10|journal=Nature Reviews Materials|doi=10.1038/s41578-021-00358-0|pages=1–17|language=en|issn=2058-8437|last3=Langer|first3=Robert|last4=Dong|first4=Yizhou|access-date=2021-11-10|archive-date=2022-05-08|archive-url=https://web.archive.org/web/20220508203607/https://www.nature.com/articles/s41578-021-00358-0}}</ref>

=== 加速 ===
因[[2019冠状病毒病疫情|2019冠状病毒病疫情]]的爆发，以及2020年初对致病病毒[[严重急性呼吸综合征冠状病毒2|SARS-CoV-2]]的测序，导致了第一批获批的mRNA疫苗的快速发展。<ref>{{Cite journal|title=The lightning-fast quest for COVID vaccines — and what it means for other diseases|url=https://www.nature.com/articles/d41586-020-03626-1|last=Ball|first=Philip|date=2020-12-18|journal=Nature|issue=7840|doi=10.1038/d41586-020-03626-1|volume=589|pages=16–18|language=en|access-date=2021-11-10|archive-date=2022-05-13|archive-url=https://web.archive.org/web/20220513053206/https://www.nature.com/articles/d41586-020-03626-1}}</ref> [[BioNTech|BioNTech]]和[[莫德纳|Moderna]]在同年12月获得了其基于mRNA的COVID-19疫苗的批准。12月2日，在其最后的八周试验后七天，英国药品和保健品管理局成为历史上第一个批准mRNA疫苗的全球药品监管机构，对[[輝瑞|輝瑞]]和[[BioNTech|生物技术公司]]联合研发的[[辉瑞－BioNTech_2019冠状病毒病疫苗|辉瑞－BioNTech 2019冠状病毒病疫苗]]给予了紧急使用授权，以供广泛使用。<ref name="#4"/> <ref name="#5"/>12月11日，[[美国食品药品监督管理局|美国食品药品监督管理局]]对[[輝瑞|輝瑞]]和[[BioNTech|生物技术公司]]联合研发的COVID-19疫苗[[辉瑞－BioNTech_2019冠状病毒病疫苗|辉瑞－BioNTech疫苗]]给予紧急使用授权，一周后对[[莫德纳|Moderna]]的COVID-19疫苗也给予了类似批准。<ref>{{Cite journal|title=Comirnaty and Pfizer-BioNTech COVID-19 Vaccine|url=https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine|last=Commissioner|first=Office of the|date=2021-11-09|journal=FDA|language=en|access-date=2021-11-10|archive-date=2021-10-22|archive-url=https://web.archive.org/web/20211022105147/https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine}}</ref>

==作用机制==
疫苗的目标是刺激适应性免疫系统产生精确针对该特定病原体的抗体。抗体所针对的病原体上的标记被称为抗原<ref>{{Cite journal|title=Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733686/|last=Batty|first=Cole J.|last2=Heise|first2=Mark T.|date=2021-2|journal=Advanced Drug Delivery Reviews|doi=10.1016/j.addr.2020.12.006|volume=169|pages=168–189|issn=0169-409X|pmc=7733686|pmid=33316346|last3=Bachelder|first3=Eric M.|last4=Ainslie|first4=Kristy M.|access-date=2021-11-10|archive-date=2021-02-11|archive-url=https://web.archive.org/web/20210211054938/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733686/}}</ref>。

传统疫苗通过将抗原、减毒（弱化）病毒、灭活（死亡）病毒或重组抗原编码病毒载体（带有抗原转基因的无害载体病毒）注射到体内来刺激抗体反应。这些抗原和病毒是在体外制备和生长的<ref>{{Cite journal|title=SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900244/|last=Kyriakidis|first=Nikolaos C.|last2=López-Cortés|first2=Andrés|date=2021-02-22|journal=NPJ Vaccines|doi=10.1038/s41541-021-00292-w|volume=6|pages=28|issn=2059-0105|pmc=7900244|pmid=33619260|last3=González|first3=Eduardo Vásconez|last4=Grimaldos|first4=Alejandra Barreto|last5=Prado|first5=Esteban Ortiz|access-date=2021-11-10|archive-date=2022-03-25|archive-url=https://web.archive.org/web/20220325182755/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900244/}}</ref>。

与此相反，mRNA疫苗是将短命的<ref>{{Cite journal|title=Tools for translation: non-viral materials for therapeutic mRNA delivery|url=https://www.nature.com/articles/natrevmats201756|last=Hajj|first=Khalid A.|last2=Whitehead|first2=Kathryn A.|date=2017-09-12|journal=Nature Reviews Materials|issue=10|doi=10.1038/natrevmats.2017.56|volume=2|pages=1–17|language=en|issn=2058-8437|access-date=2021-11-10|archive-date=2022-04-26|archive-url=https://web.archive.org/web/20220426004604/https://www.nature.com/articles/natrevmats201756}}</ref>病毒RNA序列的合成片段引入被接种者体内。这些mRNA片段通过吞噬作用被树突状细胞吸收。<ref name="#8">{{Cite journal|title=Developing mRNA-vaccine technologies|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3597572/|last=Schlake|first=Thomas|last2=Thess|first2=Andreas|date=2012-11-01|journal=RNA Biology|issue=11|doi=10.4161/rna.22269|volume=9|pages=1319–1330|issn=1547-6286|pmc=3597572|pmid=23064118|last3=Fotin-Mleczek|first3=Mariola|last4=Kallen|first4=Karl-Josef|access-date=2021-11-10|archive-date=2021-01-07|archive-url=https://web.archive.org/web/20210107071426/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3597572/}}</ref>树突状细胞利用其内部机器（核糖体）读取mRNA并产生mRNA所编码的病毒抗原。 <ref>{{Cite journal|title=Review the safety of Covid-19 mRNA vaccines: a review|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087878/|last=Anand|first=Pratibha|last2=Stahel|first2=Vincent P.|date=2021-05-01|journal=Patient Safety in Surgery|doi=10.1186/s13037-021-00291-9|volume=15|pages=20|issn=1754-9493|pmc=8087878|pmid=33933145|access-date=2021-11-10|archive-date=2021-10-16|archive-url=https://web.archive.org/web/20211016164252/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087878/}}</ref> 尽管非免疫细胞也有可能吸收疫苗mRNA，产生抗原，并在其表面显示抗原，但树突状细胞更容易吸收mRNA球体。<ref>{{Cite web|title=How do the new COVID-19 vaccines work?|url=https://scopeblog.stanford.edu/2020/12/22/how-do-the-new-covid-19-vaccines-work/|access-date=2021-11-10|date=2020-12-22|last=Goldman|first=Author Bruce|work=Scope|language=en-US|archive-date=2021-01-30|archive-url=https://web.archive.org/web/20210130053157/https://scopeblog.stanford.edu/2020/12/22/how-do-the-new-covid-19-vaccines-work/}}</ref>mRNA片段在细胞质中翻译，不影响人体的基因组DNA，它单独位于细胞核中。<ref>{{Cite journal|title=mRNA Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection|url=https://www.mdpi.com/1422-0067/21/18/6582|last=Xu|first=Shuqin|last2=Yang|first2=Kunpeng|date=2020-01|journal=International Journal of Molecular Sciences|issue=18|doi=10.3390/ijms21186582|volume=21|pages=6582|language=en|last3=Li|first3=Rose|last4=Zhang|first4=Lu|access-date=2021-11-10|archive-date=2022-04-29|archive-url=https://web.archive.org/web/20220429120920/https://www.mdpi.com/1422-0067/21/18/6582}}</ref>

一旦病毒抗原由宿主细胞产生，正常的适应性免疫系统过程就会随之进行。抗原被蛋白酶分解。I类和II类MHC分子然后附着在抗原上，并将其运送到细胞膜上，"激活 "树突状细胞。 一旦激活，树突状细胞迁移到淋巴结，在那里它们将抗原呈现给T细胞和B细胞。<ref>{{Cite book|chapter=mRNA Cancer Vaccines|last=Fiedler|editor-first=Wolfgang|last5=Heidenreich|first5=Regina|last4=Rauch|first4=Susanne|last3=Lutz|first3=Johannes|last2=Lazzaro|first2=Sandra|first=Katja|title=Current Strategies in Cancer Gene Therapy|language=en|doi=10.1007/978-3-319-42934-2_5|pages=61–85|isbn=978-3-319-42934-2|location=Cham|date=2016|publisher=Springer International Publishing|url=https://doi.org/10.1007/978-3-319-42934-2_5|series=Recent Results in Cancer Research|editor-last=Walther}}</ref>

==优点==

=== 传统疫苗 ===
与传统疫苗相比，mRNA疫苗具有特殊的优势。因为mRNA疫苗不是由活性病原体（甚至是灭活的病原体）构建的，所以它们是无传染性的。相比之下，传统疫苗需要生产病原体，如果大量生产，可能会增加生产设施局部爆发病毒的风险。<ref name="#3"/> mRNA疫苗的另一个生物学优势是，由于抗原在细胞内产生，它们会刺激细胞免疫，以及体液免疫。<ref>{{Cite journal|title=COVID-19 vaccines poised for launch, but impact on pandemic unclear|url=https://www.nature.com/articles/d41587-020-00022-y|last=Dolgin|first=Elie|date=2020-11-25|journal=Nature Biotechnology|doi=10.1038/d41587-020-00022-y|language=en|access-date=2021-11-10|archive-date=2020-12-09|archive-url=https://web.archive.org/web/20201209062505/https://www.nature.com/articles/d41587-020-00022-y}}</ref>

mRNA疫苗的生产优势是可以迅速设计。Moderna公司在2天内就为COVID-19设计了mRNA-1273疫苗。<ref>{{Cite web|title=Moderna's groundbreaking coronavirus vaccine was designed in just 2 days|url=https://www.businessinsider.com/moderna-designed-coronavirus-vaccine-in-2-days-2020-11|access-date=2021-11-10|last=Bendix|first=Susie Neilson, Andrew Dunn, Aria|work=Business Insider|language=en-US|archive-date=2022-05-13|archive-url=https://web.archive.org/web/20220513124104/https://www.businessinsider.com/moderna-designed-coronavirus-vaccine-in-2-days-2020-11}}</ref>它们还可以更快、更便宜、更标准化地生产（生产中的错误率更低），这可以提高对严重疫情的反应能力 。

辉瑞-生物技术公司的疫苗最初需要110天才能大规模生产（在辉瑞公司开始优化生产过程，只需60天），这大大快于传统的流感和脊髓灰质炎疫苗。 <ref>{{Cite web|title=A COVID-19 vaccine life cycle: from DNA to doses|url=https://www.usatoday.com/in-depth/news/health/2021/02/07/how-covid-vaccine-made-step-step-journey-pfizer-dose/4371693001/|access-date=2021-11-10|work=www.usatoday.com|language=en|archive-date=2021-02-25|archive-url=https://web.archive.org/web/20210225063937/https://www.usatoday.com/in-depth/news/health/2021/02/07/how-covid-vaccine-made-step-step-journey-pfizer-dose/4371693001/}}</ref> 在这个较大的时间范围内，实际生产时间只有22天左右：两周用于DNA质粒的分子克隆和DNA的纯化，四天用于DNA到RNA的转录和mRNA的纯化，四天用于将mRNA封装在脂质纳米颗粒中，然后进行填充和完成。<ref>{{Cite web|title=From science to syringe: COVID-19 vaccines are miracles of science and supply chains|url=https://www.ctvnews.ca/health/coronavirus/from-science-to-syringe-covid-19-vaccines-are-miracles-of-science-and-supply-chains-1.5327003|access-date=2021-11-10|date=2021-02-27|last=Rabson|first=Mia|work=Coronavirus|language=en|archive-date=2021-02-27|archive-url=https://web.archive.org/web/20210227181528/https://www.ctvnews.ca/health/coronavirus/from-science-to-syringe-covid-19-vaccines-are-miracles-of-science-and-supply-chains-1.5327003}}</ref>每次生产所需的大部分时间都分配给每个阶段严格的质量控制。

=== DNA疫苗 ===
除了分享理论上DNA疫苗相对于既定传统疫苗的优势外，mRNA疫苗还具有比DNA疫苗更多的优势。mRNA在细胞液中反應，因此不需要RNA进入细胞核，避免了被整合到宿主基因组中的风险。修饰的核苷（例如，假尿苷，2'-O-甲基化的核苷）可以被纳入mRNA中，以抑制免疫反应刺激，避免立即降解，并通过增强翻译能力产生更持久的效果。 <ref>{{Cite book|chapter=Nucleoside Modified mRNA Vaccines for Infectious Diseases|doi=10.1007/978-1-4939-6481-9_6|editor-first=Thomas|last2=Weissman|first2=Drew|last=Pardi|first=Norbert|language=en|pages=109–121|title=RNA Vaccines: Methods and Protocols|isbn=978-1-4939-6481-9|location=New York, NY|date=2017|publisher=Springer|url=https://doi.org/10.1007/978-1-4939-6481-9_6|series=Methods in Molecular Biology|editor-last=Kramps}}</ref><ref>{{Cite journal|title=Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3241667/|last=Karikó|first=Katalin|last2=Muramatsu|first2=Hiromi|date=2011-11|journal=Nucleic Acids Research|issue=21|doi=10.1093/nar/gkr695|volume=39|pages=e142|issn=0305-1048|pmc=3241667|pmid=21890902|last3=Ludwig|first3=János|last4=Weissman|first4=Drew|access-date=2021-11-10|archive-date=2021-03-10|archive-url=https://web.archive.org/web/20210310235317/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3241667/}}</ref> mRNA的开放阅读框架（ORF）和非翻译区（UTR）可以为不同的目的进行优化（这一过程称为mRNA的序列工程），例如通过丰富鸟嘌呤-胞嘧啶含量或选择已知可增加翻译的特定UTR。<ref name="#8"/> 可以增加编码复制机制的额外ORF以扩大抗原翻译，从而提高免疫反应，减少所需的起始材料数量。<ref>{{Cite journal|title=Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835025/|last=Vogel|first=Annette B.|last2=Lambert|first2=Laura|date=2018-02-07|journal=Molecular Therapy|issue=2|doi=10.1016/j.ymthe.2017.11.017|volume=26|pages=446–455|issn=1525-0016|pmc=5835025|pmid=29275847|last3=Kinnear|first3=Ekaterina|last4=Busse|first4=David|last5=Erbar|first5=Stephanie|last6=Reuter|first6=Kerstin C.|last7=Wicke|first7=Lena|last8=Perkovic|first8=Mario|last9=Beissert|first9=Tim|access-date=2021-11-10|archive-date=2021-08-09|archive-url=https://web.archive.org/web/20210809222936/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835025/}}</ref><ref>{{Cite journal|title=Enhancing immune responses using suicidal DNA vaccines|url=https://www.nature.com/articles/nbt0698-562|last=Berglund|first=Peter|last2=Smerdou|first2=Cristian|date=1998-06|journal=Nature Biotechnology|issue=6|doi=10.1038/nbt0698-562|volume=16|pages=562–565|language=en|issn=1546-1696|last3=Fleeton|first3=Marina N.|last4=Tubulekas|first4=Loannis|last5=Liljeström|first5=Peter|access-date=2021-11-10|archive-date=2021-03-08|archive-url=https://web.archive.org/web/20210308131124/https://www.nature.com/articles/nbt0698-562}}</ref>

==缺点==
=== 储存 ===
由于mRNA是脆弱的，一些疫苗必须保存在非常低的温度下，以避免降解而令接種者获得很少的有效免疫力。辉瑞生物技术公司的[[BNT162b2|BNT162b2]] mRNA疫苗必须保存在-80至-60 °C（-112至-76 °F）之间。<ref>{{Cite web|title=Label Update: Effective 10/29/21 THREE VACCINE PRESENTATIONS ARE NOW AVAILABLE|url=https://www.cvdvaccine-us.com/product-storage-and-dry-ice|access-date=2021-11-10|archive-date=2021-01-24|archive-url=https://web.archive.org/web/20210124024401/https://www.cvdvaccine-us.com/product-storage-and-dry-ice}}</ref> <ref name="#9">{{Cite news|title=Why Does Pfizer's COVID-19 Vaccine Need To Be Kept Colder Than Antarctica?|url=https://www.npr.org/sections/health-shots/2020/11/17/935563377/why-does-pfizers-covid-19-vaccine-need-to-be-kept-colder-than-antarctica|newspaper=NPR.org|accessdate=2021-11-10|language=en|archive-date=2021-02-01|archive-url=https://web.archive.org/web/20210201172940/https://www.npr.org/sections/health-shots/2020/11/17/935563377/why-does-pfizers-covid-19-vaccine-need-to-be-kept-colder-than-antarctica}}</ref>Moderna说他们的[[mRNA-1273|mRNA-1273]]疫苗可以保存在-25至-15 °C（-13至5 °F）之间，<ref>{{Cite book|title=ACT SHEET FOR HEALTHCARE PROVIDERS ADMINISTERING VACCINE (VACCINATION PROVIDERS) EMERGENCY USE AUTHORIZATION (EUA) OF THE MODERNA COVID-19 VACCINE TO PREVENT CORONAVIRUS DISEASE 2019 (COVID-19)|url=https://www.fda.gov/media/144637/download|access-date=2021-11-10|archive-date=2021-08-14|archive-url=https://web.archive.org/web/20210814043120/https://www.fda.gov/media/144637/download}}</ref> 这与家用冰箱相当，<ref name="#9"/> 而且它在2至8 °C（36至46 °F）之间保持稳定，最长可达30天。 <ref>{{Cite web|title=Moderna Announces Longer Shelf Life for its COVID-19 Vaccine Candidate at Refrigerated Temperatures {{!}} Moderna, Inc.|url=https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-longer-shelf-life-its-covid-19-vaccine/|access-date=2021-11-10|work=investors.modernatx.com|language=en|archive-date=2020-11-16|archive-url=https://web.archive.org/web/20201116154303/https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-longer-shelf-life-its-covid-19-vaccine/}}</ref> 2020年11月，[[科學期刊|科學期刊雜誌]]《[[自然_(期刊)|自然]]》报道：「虽然LNP配方或mRNA二级结构的差异可能是Moderna和BioNtech之间]热稳定性差异的原因，但许多专家怀疑两种疫苗产品最终将证明在各种温度条件下具有类似的储存要求和保质期。」目前正在研究可能允许在更高温度下储存的几个平台。

=== 近期 ===
在2020年之前，没有任何 mRNA 技术平台（药物或疫苗）被授权用于人类，因此存在未知影响的风险。2020 年 COVID-19 大流行要求 mRNA 疫苗具有更快的生产能力，使其对国家卫生组织具有吸引力，并导致了关于 mRNA 疫苗在八周的最终人体试验后应获得何种类型的初始授权（包括紧急使用授权或扩大使用授权）的辩论。<ref>{{Cite news|title=Pfizer boss warns on risk of fast-tracking vaccines|url=https://www.ft.com/content/1a91c897-66d5-4bd5-ae9b-0b3be185dac8|newspaper=Financial Times|date=2020-09-03|accessdate=2021-11-10|first=Hannah|last=Kuchler|archive-date=2020-11-18|archive-url=https://web.archive.org/web/20201118103242/https://www.ft.com/content/1a91c897-66d5-4bd5-ae9b-0b3be185dac8}}</ref>

=== 副作用 ===
反应原性与传统的、非RNA疫苗相似。然而，那些易受自身免疫反应影响的人可能会对mRNA疫苗产生不良反应。疫苗中的mRNA链可能会引起意外的免疫反应--这需要身体认为自己生病了，而人也因此感觉自己生病了。为了尽量减少这种情况，mRNA疫苗中的mRNA序列被设计成模仿宿主细胞产生的序列。

在新型COVID-19 mRNA疫苗的试验中报告了强烈但短暂的反应性效应；大多数人不会出现严重的副作用，包括发烧和疲劳。严重的副作用是指那些妨碍日常活动的副作用<ref>{{Cite journal|title=Public needs to prep for vaccine side effects|url=https://www.science.org/doi/10.1126/science.370.6520.1022|last=Wadman|first=Meredith|date=2020-11-27|journal=Science|issue=6520|doi=10.1126/science.370.6520.1022|volume=370|pages=1022–1022|access-date=2021-11-10|archive-date=2022-04-15|archive-url=https://web.archive.org/web/20220415045059/https://www.science.org/doi/10.1126/science.370.6520.1022}}</ref>。

2021年11月8日法国医疗保险机构社会健康保险总局（CNAM）与法国药品安全局公布一项最新病例研究报告，确认新冠信使核糖核酸（mRNA）疫苗会增加发生心肌炎和心包炎的风险<ref>{{Cite web|title=法一项研究确认mRNA疫苗提高心肌炎和心包炎风险|url=https://www.rfi.fr/cn/%E6%B3%95%E5%9B%BD/20211108-%E6%B3%95%E4%B8%80%E9%A1%B9%E7%A0%94%E7%A9%B6%E7%A1%AE%E8%AE%A4mrna%E7%96%AB%E8%8B%97%E6%8F%90%E9%AB%98%E5%BF%83%E8%82%8C%E7%82%8E%E5%92%8C%E5%BF%83%E5%8C%85%E7%82%8E%E9%A3%8E%E9%99%A9|access-date=2021-11-10|date=2021-11-08|work=RFI - 法国国际广播电台|language=zh-Hans|archive-date=2021-11-24|archive-url=https://web.archive.org/web/20211124201157/https://www.rfi.fr/cn/%E6%B3%95%E5%9B%BD/20211108-%E6%B3%95%E4%B8%80%E9%A1%B9%E7%A0%94%E7%A9%B6%E7%A1%AE%E8%AE%A4mrna%E7%96%AB%E8%8B%97%E6%8F%90%E9%AB%98%E5%BF%83%E8%82%8C%E7%82%8E%E5%92%8C%E5%BF%83%E5%8C%85%E7%82%8E%E9%A3%8E%E9%99%A9}}</ref>

== 有效力 ==
Moderna和Pfizer-BioNTech的COVID-19 mRNA疫苗的有效率达90%至95%。之前对COVID-19以外的病原体进行的mRNA药物试验并不有效，不得不在试验的早期阶段就放弃了。新的mRNA疫苗疗效的原因尚不清楚<ref name="#10">{{Cite web|title=The Promise of mRNA Vaccines|url=https://www.the-scientist.com/news-opinion/the-promise-of-mrna-vaccines-68202|access-date=2021-11-10|work=The Scientist Magazine®|language=en|archive-date=2021-01-22|archive-url=https://web.archive.org/web/20210122140828/https://www.the-scientist.com/news-opinion/the-promise-of-mrna-vaccines-68202}}</ref>。

医生科学家Margaret Liu说，新的COVID-19 mRNA疫苗的疗效可能是由于投入开发的 "大量资源"，或者疫苗可能是 "引发了对mRNA的非特异性炎症反应，可能是提高了其特异性免疫反应。鉴于改良的核苷技术减少了炎症，但并没有完全消除它"，而且 "这也可以解释一些接受mRNA SARS-CoV-2疫苗的人所报告的强烈反应，如疼痛和发烧"。这些反应虽然很严重，但都是短暂的，另一种观点认为它们是对脂质药物输送分子的反应<ref name="#10"/>。

== 争议 ==
曾有謠言指出，mRNA疫苗可以改变细胞核中的DNA<ref>{{Cite news|title=Vaccine rumours debunked: Microchips, 'altered DNA' and more|url=https://www.bbc.com/news/54893437|newspaper=BBC News|date=2020-12-02|accessdate=2021-11-10|language=en-GB|archive-date=2021-02-01|archive-url=https://web.archive.org/web/20210201052252/https://www.bbc.com/news/54893437}}</ref>，而事實上细胞体中的mRNA在有时间进入细胞核之前就会非常迅速地被降解。故此mRNA疫苗必须储存在非常低的温度下以防止mRNA降解。逆转录病毒可以是单链RNA（正如SARS-CoV-2疫苗是单链RNA），它进入细胞核并使用逆转录酶从细胞核中的RNA制造DNA。逆转录病毒有被导入细胞核的机制，但其他mRNA缺乏这些机制。一旦进入细胞核，没有引物就不能从RNA中生成DNA，引物伴随着逆转录病毒，但如果放在细胞核中，其他mRNA就不存在引物了<ref>{{Cite journal|title=Retroviral DNA Transposition: Themes and Variations|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383315/|last=Skalka|first=Anna Marie|date=2014-12|journal=Microbiology spectrum|issue=5|doi=10.1128/microbiolspec.MDNA3-0005-2014|volume=2|pages=MDNA3–0005–2014|issn=2165-0497|pmc=4383315|pmid=25844274}}</ref> 。

== 疫苗种类 ==
两大类mRNA疫苗使用非扩增（常规）mRNA或自扩增mRNA。<ref name="#11">{{Cite journal|title=Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines|url=https://doi.org/10.1517/17425247.2014.901308|last=Deering|first=Raquel P|last2=Kommareddy|first2=Sushma|date=2014-06-01|journal=Expert Opinion on Drug Delivery|issue=6|doi=10.1517/17425247.2014.901308|volume=11|pages=885–899|issn=1742-5247|pmid=24665982|last3=Ulmer|first3=Jeffrey B|last4=Brito|first4=Luis A|last5=Geall|first5=Andrew J}}</ref> 前两个获批的mRNA疫苗（辉瑞生物技术公司和Moderna COVID-19疫苗）使用非扩增mRNA。这两种mRNA类型都在继续研究，作为针对其他潜在病原体和癌细胞的疫苗方法<ref name="#7"/>。

=== 非扩增mRNA ===
传统的mRNA疫苗使用非扩增性mRNA结构。 非扩增性mRNA只有一个开放阅读框，编码感兴趣的抗原蛋白。<ref name="#11"/> 细胞使用的mRNA总量等于疫苗传递的mRNA量。在传统的mRNA疫苗中，剂量强度受疫苗所能传递的mRNA数量的限制<ref>{{Cite journal|title=Enlisting the mRNA Vaccine Platform to Combat Parasitic Infections|url=https://www.mdpi.com/2076-393X/7/4/122|last=Versteeg|first=Leroy|last2=Almutairi|first2=Mashal M.|date=2019-12|journal=Vaccines|issue=4|doi=10.3390/vaccines7040122|volume=7|pages=122|language=en|last3=Hotez|first3=Peter J.|last4=Pollet|first4=Jeroen|access-date=2021-11-10|archive-date=2022-04-28|archive-url=https://web.archive.org/web/20220428033653/https://www.mdpi.com/2076-393X/7/4/122}}</ref>。

=== 自扩增mRNA ===
自我复制的mRNA（saRNA）疫苗与传统的mRNA疫苗相似，不同的是，saRNA疫苗也能自我复制其mRNA。<ref>{{Cite journal|title=Self-amplifying RNA vaccines for infectious diseases|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7580817/|last=Bloom|first=Kristie|last2=van den Berg|first2=Fiona|date=2020-10-22|journal=Gene Therapy|doi=10.1038/s41434-020-00204-y|pages=1–13|issn=0969-7128|pmc=7580817|pmid=33093657|last3=Arbuthnot|first3=Patrick|access-date=2021-11-10|archive-date=2022-04-26|archive-url=https://web.archive.org/web/20220426200044/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7580817/}}</ref> 自我复制的mRNA有两个开放阅读框。第一个开放阅读框，像传统的mRNA一样，对感兴趣的抗原蛋白进行编码。第二个开放阅读框为RNA依赖性RNA聚合酶（及其辅助蛋白）编码，该聚合酶在细胞内自我复制mRNA结构，并创造多个自我复制。这使得较小数量的mRNA可用于疫苗传递。自我复制mRNA的机制和评估可能是不同的，因为自我复制的mRNA在大小上是一个大得多的分子，这从根本上是不同的。

不同的saRNA疫苗正在被研究，包括疟疾疫苗的开发。<ref>{{Cite web|title=A Malaria Vaccine Candidate|url=https://www.science.org/content/blog-post/malaria-vaccine-candidate|access-date=2021-11-10|work=www.science.org|language=en|archive-date=2021-11-10|archive-url=https://web.archive.org/web/20211110150430/https://www.science.org/content/blog-post/malaria-vaccine-candidate}}</ref> Gritstone生物公司在2021年开始了saRNA COVID-19疫苗的一期试验，作为加强型疫苗使用。该疫苗旨在针对SARS-CoV-2病毒的尖峰蛋白，以及可能不太容易发生基因变异的病毒蛋白，以提供对SARS-CoV-2变种的更大保护。<ref>{{Cite web|title=The Biologics News and Reports Portal|url=https://pipelinereview.com/|access-date=2021-11-10|last=Martin|first=Ulrich|work=pipelinereview|language=en-gb|archive-date=2021-11-10|archive-url=https://web.archive.org/web/20211110171604/https://pipelinereview.com/}}</ref><ref>{{Cite news|title=First 'variant-proof' Covid vaccine starts trials in Manchester|url=https://www.telegraph.co.uk/news/2021/09/20/first-variant-proof-covid-vaccine-starts-trials-manchester/|newspaper=The Telegraph|date=2021-09-20|accessdate=2021-11-10|issn=0307-1235|language=en-GB|first=Sarah|last=Knapton|archive-date=2021-09-20|archive-url=https://web.archive.org/web/20210920201310/https://www.telegraph.co.uk/news/2021/09/20/first-variant-proof-covid-vaccine-starts-trials-manchester/}}</ref>

==参见==
*[[DNA疫苗|DNA疫苗]]
*[[BNT162|BNT162b2]]，首款完成開發及投入應用的RNA疫苗，用于预防2019冠状病毒病
*[[莫德纳2019冠状病毒病疫苗|MRNA-1273]]，繼「BNT162b2」後另一款预防2019冠状病毒病的RNA疫苗
*[[癌症疫苗|癌症疫苗]]

==参考文献==
{{reflist|30em}}

{{Vaccines}}
{{Authority control}}

[[Category:RNA疫苗|*]]
[[Category:RNA|Category:RNA]]